The primary objective of this study is to assess the retention rate of perampanel when given as secondary monotherapy in routine clinical care.
This study is a retrospective study of participants who received perampanel as primary or secondary monotherapy at approximately 40 centers in Europe, Asia, and Australia. Primary monotherapy is defined as the administration of perampanel in the absence of any concomitant antiepileptic drugs (AEDs). Secondary (conversion) monotherapy is defined as the conversion of perampanel from adjunctive therapy to monotherapy by withdrawing concomitant AEDs.
Study Type
OBSERVATIONAL
Enrollment
61
Retention rate
The percentage of participants remaining on perampanel monotherapy treatment after conversion from perampanel adjunctive therapy
Time frame: Month 3
Retention rate
The percentage of participants remaining on perampanel monotherapy treatment after conversion from perampanel adjunctive therapy
Time frame: Month 6
Retention rate
The percentage of participants remaining on perampanel monotherapy treatment after conversion from perampanel adjunctive therapy
Time frame: Month 12
Retention rate
The percentage of participants remaining on perampanel monotherapy treatment after conversion from perampanel adjunctive therapy
Time frame: Month 18
Retention rate
The percentage of participants remaining on perampanel monotherapy treatment after conversion from perampanel adjunctive therapy
Time frame: Month 24
Participants remaining on perampanel monotherapy (after conversion from perampanel as adjunctive therapy)
Time frame: Up to approximately 34 months
Percentage of participants receiving perampanel monotherapy out of the total number of participants prescribed perampanel
Time frame: Up to approximately 34 months
Percentage of participants with greater than or equal to 50% reduction in seizure frequency
Time frame: Up to approximately 34 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Percentage of participants who were seizure-free for at least 3 months
Seizure-free is defined as a terminal remission of seizures
Time frame: Up to approximately 34 months
Percentage of participants with greater than or equal to 75% reduction in seizure frequency
Time frame: Up to approximately 34 months
Percentage of participants with categorized percent reductions in seizure frequency
Time frame: Up to approximately 34 months
Percentage of participants with no change or worsening of seizures
Time frame: Up to approximately 34 months
Median percent change in seizure frequency
Time frame: Up to approximately 34 months
Percentage of participants with treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (SAEs)
Time frame: Up to approximately 34 months
Mean change in body weight
Time frame: Up to approximately 34 months
Maximum dose of perampanel during adjunctive therapy and monotherapy
Time frame: Up to approximately 34 months
Average dose of perampanel during adjunctive therapy and monotherapy
Time frame: Up to approximately 34 months